Search Results
Your search for all items matches 36145 pages
Showing 1 - 50New Prostate Cancer Risk Classification With PSMA-PET
In a study reported in The Lancet Oncology, Karpinski et al developed a new prostate cancer risk classification using PSMA-PET Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE; PPP) nomograms (PPP3) to provide prognostic values for overall survival at 3, 5, and 7 years. Study...
Benmelstobart Plus Anlotinib in First-Line Treatment for PD-L1–Positive Advanced NSCLC
In a Chinese phase III trial (CAMPASS) reported in The Lancet Oncology, Zhong et al found that the PD-L1 inhibitor benmelstobart plus the tyrosine kinase inhibitor anlotinib significantly improved progression-free survival vs placebo plus pembrolizumab in the first-line treatment of PD-L1–positive...
Kent Shih, MD, on Use of GEP for SLNB and Follow-up Planning in Melanoma
Kent Shih, MD, of Tennessee Oncology, shares three patient cases that illustrate how gene-expression profiling (GEP) in patients with melanoma helps shape the decision to proceed to sentinel lymph node biopsy (SLNB) and how often and thorough follow-up should be with medical oncology.
Kent Shih, MD, on Adjuvant Therapy in Melanoma: How Does GEP Testing Factor In?
Kent Shih, MD, of Tennessee Oncology, presents three patients cases that show how the use of gene-expression profile testing guides patient and practitioner decision-making when choosing the appropriate path of adjuvant treatment among individuals with melanoma.
Neha Vapiwala, MD, on Highlights in Prostate Cancer From ASCO GU 2026
Neha Vapiwala, MD, of the University of Pennsylvania, discusses key themes in prostate cancer data presented at this year’s symposium, including personalization of therapy, treatment sequencing considerations, the role of radiopharmaceuticals, long-term radiotherapy results, using AI and associated ...
Optical Genome Mapping Detects Additional Genetic Variants in Nearly 20% of Individuals With Acute Leukemia
New research assessing the efficacy of optical genome mapping (OGM) in a group of patients with acute leukemia has demonstrated that the method provided reliable and robust analytical performance with high sensitivity and specificity in detecting genetic alterations. In nearly 20% of cases,...
No Recurrence-Free Survival Benefit With Adjuvant Pembrolizumab in Hepatocellular Carcinoma
Recurrence-free survival was similar between adjuvant therapy with the PD-1 inhibitor pembrolizumab and placebo in patients with hepatocellular carcinoma who achieved a complete radiologic response after surgical resection or local ablation, based on the phase III KEYNOTE-937 trial.1 Presented at...
Adjuvant Pembrolizumab Plus Belzutifan May Provide a New Standard of Care for Patients With Renal Cell Carcinoma at Increased Risk of Recurrence
Based on results from the phase III KEYNOTE-564 study,1 adjuvant pembrolizumab is currently a standard of care for patients with clear cell renal cell carcinoma who have an increased risk of recurrence following a nephrectomy. Now, results from the phase III LITESPARK-022 study investigating the...
FDA Consolidates Systems Into One Cohesive Adverse Event Monitoring Tool
The U.S. Food and Drug Administration (FDA) has launched a new platform, called the FDA Adverse Event Monitoring System (AEMS), for analyzing adverse events from drugs and products. The platform consolidates multiple prior reporting systems in an effort to modernize and increase transparency into...
p53 Reactivator Rezatapopt in TP53 Y220C–Mutated Solid Tumors
In a phase I trial (PYNNACLE) reported in The New England Journal of Medicine, Dumbrava et al described the toxicity and preliminary activity of rezatapopt in TP53 Y220C–mutated solid tumors. The agent is an investigational, first-in-class, oral, selective p53 reactivator that specifically binds to ...
BCMA CAR T-Cell Therapy in Newly Diagnosed Multiple Myeloma
In a Chinese phase II study (CAREMM-001) reported in the Journal of Clinical Oncology, Yan et al found that B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy was highly active in patients with newly diagnosed multiple myeloma who were ineligible for or did not proceed...
Disease Stage at Breast Cancer Diagnosis Impacted by Region, Race, and Insurance
Significant differences were found in advanced-stage diagnoses of breast cancer in rural populations according to geographic location in the United States, which were further influenced by demographic factors of race and insurance status, according to findings from an analysis of the National...
Can Viral Respiratory Infections Increase Lung Cancer Risk?
Severe COVID-19 and influenza infections may prime the lungs for cancer and can accelerate the disease’s development—but vaccination heads off those harmful effects, according to new research published by Qian et al in Cell. University of Virginia (UVA) School of Medicine researcher Jie Sun, PhD,...
Female Reproductive Cancers Linked to Reduced Survival Advantage Over Males
A population-level cohort study of 264.4 million deaths across 20 countries found that females born since the 1930s had higher cancer mortality than males between the ages of 35 and 60 years, largely due to breast and gynecologic cancers. Although females live longer than males on average, these...
Maha H.A. Hussain, MD, FASCO, FACP, on Metastatic Castration-Resistant Prostate Cancer: BRCAAway Trial in Patients With DNA Repair Defects
Maha H.A. Hussain, MD, FASCO, FACP, of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, reviews results from the BRCAAway trial, which evaluated the efficacy of abiraterone vs olaparib vs the two agents in combination as first-line therapy for patients with metastatic...
Early Study Evaluates Two-Vaccine Strategy in T-Cell Lymphoma
T-cell lymphomas are notoriously difficult to treat because immunotherapy, despite being one of the most effective therapies for treating cancer, can’t easily distinguish cancerous T cells from healthy ones. Now, scientists at The Wistar Institute have designed a two-vaccine approach that not only...
Structured Exercise Plan for Patients With Cancer May Reduce Cognitive Effects of Chemotherapy
A structured exercise program in patients with cancer receiving chemotherapy led to a reduction in self-reported cognitive impairment vs those receiving chemotherapy who were not on an exercise plan, according to findings from a nationwide, randomized phase III trial published in JNCCN—Journal of...
Risk of Breast Cancer After Ovarian Cancer in Women With BRCA1/2 Variants
In a study reported in the Journal of Clinical Oncology, investigators from the Hereditary Breast Cancer Clinical Study Group found that women with ovarian cancer with pathogenic/likely pathogenic BRCA1/2 variants had low risk for subsequent breast cancer. Study Details The study involved an...
Metastatic Uveal Melanoma: Nivolumab/Ipilimumab Plus Percutaneous Hepatic Perfusion
In a Dutch single-center phase II trial (CHOPIN) reported in The Lancet Oncology, van den Hoek et al found that the addition of nivolumab and ipilimumab to percutaneous hepatic perfusion improved progression-free survival in patients with metastatic uveal melanoma. Study Details Seventy-six...
AI Integration in Breast Cancer Screening Increases Detection Rate, Reduces Work Burden
Integration of artificial intelligence (AI) into screening workflows increased the detection of breast cancer by 10.4% in the United Kingdom, according to the results of the GEMINI study published in Nature Cancer. Additionally, use of AI in different workflows led to reductions in workload by up...
Douglas R. Lowy, MD, and John T. Schiller, PhD, Honored With the 2026 Pezcoller Foundation–AACR International Award for Extraordinary Achievement in Cancer Research
The Pezcoller Foundation–American Association for Cancer Research (AACR) International Award for Extraordinary Achievement in Cancer Research will be presented to Douglas R. Lowy, MD, and John T. Schiller, PhD, during the AACR Annual Meeting 2026, to be held April 17 to 22 at the San Diego...
Prostate Cancer: Low Testosterone Levels May Be Associated With Increased Risk of Progression During Surveillance
A new study has found that patients with prostate cancer and low testosterone levels may have a higher risk of their cancer progressing to a more aggressive form while under active surveillance. The findings, published by Lawen et al in the The Journal of Urology, suggest that baseline testosterone ...
Stanford Names Leader for Drug Development and Precision Oncology
Vivek Subbiah, MD, has been appointed as the inaugural associate director for drug development and precision oncology at the Stanford Cancer Institute, with a planned start date in spring 2026. In this role, he will lead the Early Drug Development Program to expand access to innovative treatments...
FDA Releases Updated Guidance on Biosimilar Development
The U.S. Food and Drug Administration (FDA) has released a new draft guidance to streamline the development of biosimilars. This, and prior versions of the draft guidance for industry, reflect actions being taken by the agency to lower the cost of drugs. “Streamlining biosimilar development...
Neoadjuvant Sacituzumab Govitecan Plus Perioperative Pembrolizumab in Muscle-Invasive Bladder Cancer
In an Italian single-center phase II trial (SURE-02) reported in The Lancet Oncology, Necchi et al found that neoadjuvant sacituzumab govitecan-hziy plus perioperative pembrolizumab produced a “promising” clinical complete response rate in patients with muscle-invasive bladder cancer who were...
SABCS 2025: High-Level Review of Select Data
The 2025 San Antonio Breast Cancer Symposium (SABCS 2025) featured some exciting presentations. The early breast cancer highlights at SABCS 2025 included the landmark lidERA trial, which explored the efficacy of the oral selective estrogen receptor degrader (SERD) giredestrant in the adjuvant...
Addition of Axitinib to Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors
In a European phase II/III trial (AXINET) reported in the Journal of Clinical Oncology, Garcia-Carbonero et al found that the addition of axitinib to long-acting octreotide appeared to show activity in patients with advanced extrapancreatic neuroendocrine tumors (epNETs). Study Details The...
Prostate Cancer: Does Taking ARPIs and Anticoagulants Together Raise Risks?
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors (ARPIs) and different types of anticoagulants, investigators found no evidence of an increase in patients’ bleeding or clotting risks, despite previous lab results that raised alarms. These findings were...
Case 3: Perioperative Management of Resectable EGFR-Mutant NSCLC
This is Part 3 of Optimizing the Care Continuum for EGFR-Mutant NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Suresh Ramalingam, Zofia Piotrowska, and Helena Yu discuss the perioperative management of resectable...
Case 2: Acquired Resistance After First-Line Osimertinib-Based Therapy in EGFR L858R–Mutant NSCLC
This is Part 2 of Optimizing the Care Continuum for EGFR-Mutant NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Suresh Ramalingam, Zofia Piotrowska, and Helena Yu discuss the management of acquired resistance after...
Case 1: First-Line Therapy for EGFR-Mutant Metastatic NSCLC
This is Part 1 of Optimizing the Care Continuum for EGFR-Mutant NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Suresh Ramalingam, Zofia Piotrowska, and Helena Yu discuss the first-line treatment of EGFR-mutant non–small ...
Peter WT Pisters, MD, Honored With Top Award From Society of Surgical Oncology
Peter WT Pisters, MD, President of The University of Texas MD Anderson Cancer Center, was honored with the Charles M. Balch, MD, Distinguished Service Award at the Society of Surgical Oncology (SSO) 2026 Annual Meeting in recognition of his substantial contributions and leadership in the field...
AI-Backed Liquid Biopsies Identify Liver Diseases
Building upon the foundation of liquid biopsy utility for the early detection of cancer, analysis of genome-wide cell-free DNA fragmentation with machine learning classification and modeling can also extend to the identification of liver cirrhosis and other chronic diseases, according to findings...
TACE With Camrelizumab and Rivoceranib in Unresectable Hepatocellular Carcinoma
In a Chinese phase II trial (CHANCE2005/CARES-005) reported in the Journal of Clinical Oncology, Zhu et al found that the addition of camrelizumab and rivoceranib to transarterial chemoembolization (TACE) improved progression-free survival in patients with unresectable hepatocellular carcinoma....
Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs
Researchers have identified that the reporting of venous and arterial thrombotic events in cancer clinical trials is inconsistent and potentially inaccurate, according to a comments article published in the Journal of Clinical Oncology.1 “Mandatory and uniform reporting of all [venous and arterial...
Cumulative Incidence of Advanced Breast Cancer in Japanese Women Aged 40 to 49 Years With Addition of Ultrasonography to Mammography Screening
As reported in The Lancet by Harada-Shoji et al, the Japanese J-START trial showed that adjunctive ultrasonography was associated with a reduced cumulative incidence of advanced breast cancer vs mammography alone in screening of asymptomatic women aged 40 to 49 years. Initial reports from the trial ...
HPV Vaccination Protection From Cervical Cancer Sustained Long Term
Quadrivalent human papillomavirus (HPV) vaccination led to a significantly reduced risk of invasive cervical cancer that was sustained through long-term follow-up, according to the results of a Swedish nationwide, register-based cohort study published in The BMJ. “This study provides evidence of...
Five-Year Outcomes With First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma
As reported in the Journal of Clinical Oncology by Scherpereel et al, 5-year findings from the phase III CheckMate 743 trial showed continued overall survival benefit of first-line nivolumab plus ipilimumab vs chemotherapy in patients with unresectable pleural mesothelioma. Study Details In the...
FDA Approves Teclistamab and Daratumumab For Relapsed or Refractory Multiple Myeloma
On March 5, 2026, the U.S. Food and Drug Administration (FDA) approved teclistamab (Tecvayli) in combination with daratumumab hyaluronidase-fihj for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a...
Activity Observed with Novel KRAS Inhibitor in Pancreatic Cancer
A novel KRAS G12D inhibitor produced disease control in almost 80% of patients with heavily pretreated advanced or metastatic KRAS G12D–mutated pancreatic cancer in an early-phase study reported at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium.1 Of 41 evaluable patients treated with...
Short-Term Vaginal Estrogen Therapy Does Not Increase Risks of Endometrial Cancer Recurrence
Short-term exposure to low-dose vaginal estrogen therapy may relieve some symptoms of menopause for younger survivors of endometrial cancer without increasing the risk of endometrial cancer recurrence, according to findings from a study published in Menopause. “Early detection and improved,...
Accuracy of Molecular Inference–Based AI Model for CNS Tumor Diagnosis
In a retrospective study reported in The Lancet Oncology, Lalchungnunga et al tested the classification accuracy of a molecular inference–based artificial intelligence (AI) model (Neuropath-AI) in central nervous system (CNS) tumor diagnosis. Study Details The multi-institutional study included...
Ablation vs Surgery for Small Kidney Tumors
A large national study in Denmark following nearly 1,900 patients over almost a decade found that minimally invasive ablation is as effective as surgery for treating small kidney cancers, with faster recovery and fewer complications. Results of the study were published by Ahrenfeldt et al in...
Social Cue Prompts Reduce Sharing of Cancer Treatment Misinformation
Prompts on posts with social cues—such as messages indicating how many users have flagged a post—and clear platform review policies may encourage intervention and reduce sharing of cancer treatment misinformation on social media, according to Lazard et al, who reported findings from their online...
Colorectal Cancer: ACS Report Shows Increasing Incidence, Mortality Rates in Younger Adults
Findings from the American Cancer Society's triennial report, Colorectal Cancer Statistics, 2026, show that rates of colorectal cancer are decreasing in older adults; however, rates of colorectal cancer incidence in younger adults continue to increase, with a greater proportion of these cancers...
Research Suggests AI Pathology Models May Take Unreliable 'Shortcuts' to Identify Cancer Biomarkers
Artificial intelligence (AI) tools that detect molecular biomarker status from histologic images may be dependent upon correlational relationships with clinicopathologic features, preventing the models from learning the true causal effect of the biomarker, according to findings published in Nature...
Matthew D. Galsky, MD, FASCO, on Muscle-Invasive Bladder Cancer: Enfortumab Vedotin and Pembrolizumab
Matthew D. Galsky, MD, FASCO, of Mount Sinai Tisch Cancer Center, discusses findings from the randomized phase III KEYNOTE-B15/EV-304 study, which is evaluating neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab followed by radical cystectomy plus pelvic lymph node dissection vs...
Thomas Powles, MD, PhD, FCRP, on a Novel Antibody-Drug Conjugate in Previously Treated Advanced Urothelial Cancer
Thomas Powles, MD, PhD, FCRP, of Barts Cancer Centre, Queen Mary University of London, shares findings from the phase II RC48G001 trial of disitamab vedotin, an antibody-drug conjugate comprising a novel anti-HER2 antibody, disitamab, and an MMAE payload. The agent demonstrated “promising antitumor ...
Lisocabtagene Maraleucel in Relapsed or Refractory MZL
In a phase II trial (TRANSCEND FL) reported in The Lancet, Palomba et al found that the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel was active in patients with relapsed or refractory marginal zone lymphoma (MZL). Study Details In the international multicenter trial, 67...
Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer
As reported in The New England Journal of Medicine by Vulsteke et al, the phase III KEYNOTE-905/EV-303 trial has shown improved event-free and overall survival with the addition of perioperative enfortumab vedotin plus pembrolizumab to radical cystectomy in patients with muscle-invasive bladder...
